Analyst Ratings For NASDAQ:FENC – Fennec Pharmaceuticals (NASDAQ:FENC)
Today, HC Wainwright reiterated its Buy rating on NASDAQ:FENC – Fennec Pharmaceuticals (NASDAQ:FENC) with a price target of $18.00.
Some recent analyst ratings include
- 5/23/2018-HC Wainwright Reiterated Rating of Buy.
- 3/12/2018-Wedbush initiated coverage with a Outperform rating.
- 11/29/2017-Laidlaw initiated coverage with a Buy ➝ Buy rating.
Recent Insider Trading Activity For NASDAQ:FENC – Fennec Pharmaceuticals (NASDAQ:FENC)
NASDAQ:FENC – Fennec Pharmaceuticals (NASDAQ:FENC) has insider ownership of 9.88% and institutional ownership of 41.23%.
- On 3/28/2018 Manchester Management Pr, Llc, Major Shareholder, sold 914,745 with an average share price of $10.61 per share and the total transaction amounting to $9,705,444.45.
- On 12/12/2017 Spa Essetifin, Major Shareholder, bought 294,115 with an average share price of $8.50 per share and the total transaction amounting to $2,499,977.50.
Recent Trading Activity for NASDAQ:FENC – Fennec Pharmaceuticals (NASDAQ:FENC)
Shares of NASDAQ:FENC – Fennec Pharmaceuticals closed the previous trading session at 11.00 up +0.31 2.90% with 10.75 shares trading hands.